All In Biotech

Drug Trial Radar · NCT06372821

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

A Randomized, Participant & Investigator Blinded, Placebo-Controlled Study to Evaluate the Ability of Intrathecally Administered NIO752 to Lower CSF Total Tau Synthesis in Participants With AD Measured by Stable Isotope Labelling Kinetics

Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Nov 18, 2024

Primary completion

Jul 2026

Study completion Jul 2026

Sponsor

Lead sponsor
University College, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Washington University School of Medicine; University of Washington; Alzheimer's Association; Sigrid Rausing Trust
First posted
Apr 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage. Abnormal tau proteins cling to each other forming 'tangles' inside nerve cells, which interfere with how the nerve cells work, and eventually die. This is what causes the symptoms of dementia. It is thought that NIO752 reduces production of tau.

Conditions

  • Alzheimer Disease
  • Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder)
  • Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder)
  • Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)

Interventions

  • NIO752Drug

    Antisense oligonucleotide

  • PlaceboOther

    Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tau synthesis rate inhibition in individuals with sporadic AD and ADADTime frame: Day 23

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Washington University in St. Louis

    St Louis, Missouri · Recruiting

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.